专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

TW201833139A 抗人類ＶＩＳＴＡ抗體及其用途审中-公开
简体标题：抗人类ＶＩＳＴＡ抗体及其用途
公开(公告)号：TW201833139A
公开(公告)日：2018-09-16
申请号：TW106112834
申请日：2017-04-17
申请人：莫利麥可 , MOLLOY, MICHAEL , 羅斯泰恩傑 , ROTHSTEIN, JAY , 卡利艾爾凱瑟琳 , CARRIERE, CATHERINE , 諾艾爾藍道爾夫 J. , NOELLE, RANDOLPH J. , 迪隆沙濱娜 , DELONG, SABRINA , 萊梅西爾伊莎貝爾 , LEMERCIER, ISABELLE
发明人：莫利麥可 , MOLLOY, MICHAEL , 羅斯泰恩傑 , ROTHSTEIN, JAY , 卡利艾爾凱瑟琳 , CARRIERE, CATHERINE , 諾艾爾藍道爾夫 J. , NOELLE, RANDOLPH J. , 迪隆沙濱娜 , DELONG, SABRINA , 萊梅西爾伊莎貝爾 , LEMERCIER, ISABELLE
IPC分类号： C07K16/28
摘要：本發明提供促效性抗人類VISTA抗體及抗體片段。該等促效劑抗體及抗體片段可用於加強或增強或模擬VISTA對T細胞免疫之抑止作用且由此抑止T細胞免疫。該等促效劑抗體及抗體片段尤其適用於治療自體免疫、過敏、發炎性病況、GVHD、敗血症及移植受體。本發明亦提供用於識別該等促效劑之篩檢分析。
简体摘要：本发明提供促效性抗人类VISTA抗体及抗体片段。该等促效剂抗体及抗体片段可用于加强或增强或仿真VISTA对T细胞免疫之抑止作用且由此抑止T细胞免疫。该等促效剂抗体及抗体片段尤其适用于治疗自体免疫、过敏、发炎性病况、GVHD、败血症及移植受体。本发明亦提供用于识别该等促效剂之筛检分析。

2. 发明公开

EP3154585A2 USE OF VISTA AGONISTS AND ANTAGONISTS TO SUPPRESS OR ENHANCE HUMORAL IMMUNITY 有权转让
标题翻译： VISTA激动剂和拮抗剂减少或改善体液免疫USE
公开(公告)号：EP3154585A2
公开(公告)日：2017-04-19
申请号：EP15806089.7
申请日：2015-06-11
申请人： Green, Kathy A. , Wang, Li , Noelle, Randolph, J. , Green, William R.
发明人： Green, Kathy A. , Wang, Li , Noelle, Randolph, J. , Green, William R.
IPC分类号： A61K39/395 , C07K16/18
CPC分类号： A61K39/3955 , A61K31/198 , A61K39/39541 , A61K45/06 , C07K16/2827 , C07K2317/76 , A61K2300/00
摘要： The present invention is directed to the use of VISTA agonists alone or in association with other immune inhibitors, preferably another inhibitor of humoral immunity such as an iNOS/NO promoter or nitric oxide or a PD-1 or PD-L1 agonist or a CD40 antagonist for the treatment or prevention of conditions wherein the suppression of humoral immunity is therapeutically beneficial. The present invention is further directed to the use of VISTA antagonists alone or in association with other immune agonists, preferably another enhancer of humoral immunity such as iNOS/NO inhibitor or a PD-1 or PD-L1 antagonist or anti-CTLA-4 antibody or a CD40 agonist for the treatment or prevention of conditions wherein the enhancement of humoral immunity is therapeutically beneficial. Also, the invention relates to the use of VISTA antagonists alone or in association with another immune agonist, e.g., an iNOS/NO inhibitor or a CD40 agonist to promote the efficacy of therapeutic and prophylactic vaccines, e.g., antitumor, and antiviral vaccines.
摘要翻译：本发明涉及单独使用或与其他免疫抑制剂，体液免疫的优选另一抑制剂关联VISTA激动剂：如对iNOS / NO启动子或一氧化氮或PD-1或PD-L1激动剂或CD40拮抗用于治疗或预防的条件worin体液免疫的抑制是治疗上有益的。本发明还涉及使用单独或者与其他免疫激动剂，体液免疫的优选另一增强剂关联VISTA拮抗剂：如iNOS的/ NO抑制剂或PD-1或PD-L1拮抗剂或抗CTLA-4抗体或用于治疗或预防的状况的CD40激动剂worin体液免疫的增强是治疗上有益的。所以，本发明涉及单独使用或与另一种免疫激动剂，E. G.，iNOS的/无抑制剂或CD40激动剂的关联，以促进治疗性和预防性疫苗，E. G.，抗肿瘤和抗病毒疫苗的效力VISTA拮抗剂。

3. 发明公开

EP3154585A4 USE OF VISTA AGONISTS AND ANTAGONISTS TO SUPPRESS OR ENHANCE HUMORAL IMMUNITY 有权转让
公开(公告)号：EP3154585A4
公开(公告)日：2017-12-06
申请号：EP15806089
申请日：2015-06-11
申请人： GREEN KATHY A , WANG LI , NOELLE RANDOLPH J , GREEN WILLIAM R
发明人： GREEN KATHY A , WANG LI , NOELLE RANDOLPH J , GREEN WILLIAM R
IPC分类号： A61K31/198 , A61K39/395 , A61K45/06 , A61P35/00 , A61P37/04 , A61P37/06 , C07K16/18
CPC分类号： A61K39/3955 , A61K31/198 , A61K39/39541 , A61K45/06 , C07K16/2827 , C07K2317/76 , A61K2300/00
摘要： The present invention is directed to the use of VISTA agonists alone or in association with other immune inhibitors, preferably another inhibitor of humoral immunity such as an iNOS/NO promoter or nitric oxide or a PD-1 or PD-L1 agonist or a CD40 antagonist for the treatment or prevention of conditions wherein the suppression of humoral immunity is therapeutically beneficial. The present invention is further directed to the use of VISTA antagonists alone or in association with other immune agonists, preferably another enhancer of humoral immunity such as iNOS/NO inhibitor or a PD-1 or PD-L1 antagonist or anti-CTLA-4 antibody or a CD40 agonist for the treatment or prevention of conditions wherein the enhancement of humoral immunity is therapeutically beneficial. Also, the invention relates to the use of VISTA antagonists alone or in association with another immune agonist, e.g., an iNOS/NO inhibitor or a CD40 agonist to promote the efficacy of therapeutic and prophylactic vaccines, e.g., antitumor, and antiviral vaccines.

4. 发明专利

AU2015274504A1 Use of VISTA agonists and antagonists to suppress or enhance humoral immunity 未知
公开(公告)号：AU2015274504A1
公开(公告)日：2017-01-12
申请号：AU2015274504
申请日：2015-06-11
申请人： GREEN KATHY A , GREEN WILLIAM R , NOELLE RANDOLPH J , WANG LI
发明人： GREEN KATHY A , WANG LI , NOELLE RANDOLPH J , GREEN WILLIAM R
IPC分类号： C07K16/18 , A61K39/395
摘要： The present invention is directed to the use of VISTA agonists alone or in association with other immune inhibitors, preferably another inhibitor of humoral immunity such as an iNOS/NO promoter or nitric oxide or a PD-1 or PD-L1 agonist or a CD40 antagonist for the treatment or prevention of conditions wherein the suppression of humoral immunity is therapeutically beneficial. The present invention is further directed to the use of VISTA antagonists alone or in association with other immune agonists, preferably another enhancer of humoral immunity such as iNOS/NO inhibitor or a PD-1 or PD-L1 antagonist or anti-CTLA-4 antibody or a CD40 agonist for the treatment or prevention of conditions wherein the enhancement of humoral immunity is therapeutically beneficial. Also, the invention relates to the use of VISTA antagonists alone or in association with another immune agonist, e.g., an iNOS/NO inhibitor or a CD40 agonist to promote the efficacy of therapeutic and prophylactic vaccines, e.g., antitumor, and antiviral vaccines.

5. 发明专利

AU2015274504B2 Use of VISTA agonists and antagonists to suppress or enhance humoral immunity 未知
公开(公告)号：AU2015274504B2
公开(公告)日：2021-02-04
申请号：AU2015274504
申请日：2015-06-11
申请人： GREEN KATHY A , GREEN WILLIAM R , NOELLE RANDOLPH J , WANG LI
发明人： GREEN KATHY A , WANG LI , NOELLE RANDOLPH J , GREEN WILLIAM R
IPC分类号： C07K16/18 , A61K39/395
摘要： The present invention is directed to the use of VISTA agonists alone or in association with other immune inhibitors, preferably another inhibitor of humoral immunity such as an iNOS/NO promoter or nitric oxide or a PD-1 or PD-L1 agonist or a CD40 antagonist for the treatment or prevention of conditions wherein the suppression of humoral immunity is therapeutically beneficial. The present invention is further directed to the use of VISTA antagonists alone or in association with other immune agonists, preferably another enhancer of humoral immunity such as iNOS/NO inhibitor or a PD-1 or PD-L1 antagonist or anti-CTLA-4 antibody or a CD40 agonist for the treatment or prevention of conditions wherein the enhancement of humoral immunity is therapeutically beneficial. Also, the invention relates to the use of VISTA antagonists alone or in association with another immune agonist, e.g., an iNOS/NO inhibitor or a CD40 agonist to promote the efficacy of therapeutic and prophylactic vaccines, e.g., antitumor, and antiviral vaccines.

6. 发明专利

CA2951885A1 USE OF VISTA AGONISTS AND ANTAGONISTS TO SUPPRESS OR ENHANCE HUMORAL IMMUNITY 未知
公开(公告)号：CA2951885A1
公开(公告)日：2015-12-17
申请号：CA2951885
申请日：2015-06-11
申请人： GREEN KATHY A , WANG LI , NOELLE RANDOLPH J , GREEN WILLIAM R
发明人： GREEN KATHY A , WANG LI , NOELLE RANDOLPH J , GREEN WILLIAM R
IPC分类号： A61K39/395 , A61K31/198 , C07K16/18
摘要： The present invention is directed to the use of VISTA agonists alone or in association with other immune inhibitors, preferably another inhibitor of humoral immunity such as an iNOS/NO promoter or nitric oxide or a PD-1 or PD-L1 agonist or a CD40 antagonist for the treatment or prevention of conditions wherein the suppression of humoral immunity is therapeutically beneficial. The present invention is further directed to the use of VISTA antagonists alone or in association with other immune agonists, preferably another enhancer of humoral immunity such as iNOS/NO inhibitor or a PD-1 or PD-L1 antagonist or anti-CTLA-4 antibody or a CD40 agonist for the treatment or prevention of conditions wherein the enhancement of humoral immunity is therapeutically beneficial. Also, the invention relates to the use of VISTA antagonists alone or in association with another immune agonist, e.g., an iNOS/NO inhibitor or a CD40 agonist to promote the efficacy of therapeutic and prophylactic vaccines, e.g., antitumor, and antiviral vaccines.

7. 发明申请

WO2007056642A3 METHOD FOR MODULATING INFLAMMATORY RESPONSES 审中-公开
公开(公告)号：WO2007056642A3
公开(公告)日：2007-05-18
申请号：PCT/US2006/060427
申请日：2006-11-01
申请人： TRUSTEES OF DARTMOUTH COLLEGE , NOELLE, Randolph, J. , LU, Li-Fan , AHONEN, Cory, L.
发明人： NOELLE, Randolph, J. , LU, Li-Fan , AHONEN, Cory, L.
IPC分类号： A61K39/395
摘要： The present invention is a method for inhibiting T reg cell functional activities by blocking T reg cell-mediated mast cell activation. It has been found that IL-9 produced by T reg cells activates mast cells, which in turn mediate an amplification loop critical for graft tolerance and immune responses to tumors. Thus, a method for enhancing an immune response to a vaccine, such as a cancer vaccine, is also provided as is a method for increasing cell and humoral immunity in a subject.

8. 发明申请

WO1995006481A1 METHODS FOR INDUCING ANTIGEN-SPECIFIC T CELL TOLERANCE 审中-公开
标题翻译：诱导抗原特异性T细胞耐受性的方法
公开(公告)号：WO1995006481A1
公开(公告)日：1995-03-09
申请号：PCT/US1994009953
申请日：1994-09-02
申请人： TRUSTEES OF DARTMOUTH COLLEGE , NOELLE, Randolph, J. , FOY, Teresa, M. , DURIE, Fiona, H.
发明人： TRUSTEES OF DARTMOUTH COLLEGE
IPC分类号： A61K39/395
CPC分类号： C07K14/70578 , A61K38/00 , A61K2039/505 , A61K2039/57 , C07K16/2875 , C07K19/00 , C07K2317/24 , C07K2317/73 , C07K2319/00 , G01N33/6854
摘要： Methods for inducing antigen-specific T cell tolerance are disclosed. The methods involve contacting a T cell with: 1) a cell which presents antigen to the T cell, wherein a ligand on the cell interacts with a receptor on the surface of the T cell which mediates contact-dependent helper effector function; and 2) an antagonist of the receptor on the surface of the T cell which inhibits interaction of the ligand on the antigen presenting cell with the receptor on the T cell. In a preferred embodiment, the cell which presents antigen to the T cell is a B cell and the receptor on the surface of the T cell which mediates contact-dependent helper effector function is gp39. Preferably, the antagonist is an anti-gp39 antibody or a soluble gp39 ligand (e.g., soluble CD40). The methods of the invention can be used to induce T cell tolerance to a soluble antigen or to an allogeneic cell. The methods of the invention can also be used to induce tolerance in cases of bone marrow transplantation and other organ transplants and to inhibit graft-versus-host disease.
摘要翻译：公开了诱导抗原特异性T细胞耐受性的方法。所述方法包括使T细胞接触：1）向T细胞呈递抗原的细胞，其中细胞上的配体与介导接触依赖性辅助效应子功能的T细胞表面上的受体相互作用; 和2）T细胞表面受体的拮抗剂，其抑制抗原呈递细胞上的配体与T细胞上的受体的相互作用。在优选的实施方案中，向T细胞呈递抗原的细胞是B细胞，介导接触依赖性辅助效应子功能的T细胞表面上的受体是gp39。优选地，拮抗剂是抗gp39抗体或可溶性gp39配体（例如可溶性CD40）。本发明的方法可用于诱导对可溶性抗原或同种异体细胞的T细胞耐受性。本发明的方法还可用于在骨髓移植和其他器官移植的情况下诱导耐受性并抑制移植物抗宿主病。

9. 发明申请

WO2015191881A9 USE OF VISTA AGONISTS AND ANTAGONISTS TO SUPPRESS OR ENHANCE HUMORAL IMMUNITY 审中-公开
公开(公告)号：WO2015191881A9
公开(公告)日：2015-12-17
申请号：PCT/US2015/035371
申请日：2015-06-11
申请人： GREEN, Kathy A. , WANG, Li , NOELLE, Randolph J. , GREEN, William R.
发明人： GREEN, Kathy A. , WANG, Li , NOELLE, Randolph J. , GREEN, William R.
IPC分类号： A61K39/395 , C07K16/18
摘要： The present invention is directed to the use of VISTA agonists alone or in association with other immune inhibitors, preferably another inhibitor of humoral immunity such as an iNOS/NO promoter or nitric oxide or a PD-1 or PD-L1 agonist or a CD40 antagonist for the treatment or prevention of conditions wherein the suppression of humoral immunity is therapeutically beneficial. The present invention is further directed to the use of VISTA antagonists alone or in association with other immune agonists, preferably another enhancer of humoral immunity such as iNOS/NO inhibitor or a PD-1 or PD-L1 antagonist or anti-CTLA-4 antibody or a CD40 agonist for the treatment or prevention of conditions wherein the enhancement of humoral immunity is therapeutically beneficial. Also, the invention relates to the use of VISTA antagonists alone or in association with another immune agonist, e.g., an iNOS/NO inhibitor or a CD40 agonist to promote the efficacy of therapeutic and prophylactic vaccines, e.g., antitumor, and antiviral vaccines.

10. 发明申请

WO2015191881A3 USE OF VISTA AGONISTS AND ANTAGONISTS TO SUPPRESS OR ENHANCE HUMORAL IMMUNITY 审中-公开
公开(公告)号：WO2015191881A3
公开(公告)日：2015-12-17
申请号：PCT/US2015/035371
申请日：2015-06-11
申请人： GREEN, Kathy A. , WANG, Li , NOELLE, Randolph J. , GREEN, William R.
发明人： GREEN, Kathy A. , WANG, Li , NOELLE, Randolph J. , GREEN, William R.
IPC分类号： A61K39/395 , C07K16/18
摘要： The present invention is directed to the use of VISTA agonists alone or in association with other immune inhibitors, preferably another inhibitor of humoral immunity such as an iNOS/NO promoter or nitric oxide or a PD-1 or PD-L1 agonist or a CD40 antagonist for the treatment or prevention of conditions wherein the suppression of humoral immunity is therapeutically beneficial. The present invention is further directed to the use of VISTA antagonists alone or in association with other immune agonists, preferably another enhancer of humoral immunity such as iNOS/NO inhibitor or a PD-1 or PD-L1 antagonist or anti-CTLA-4 antibody or a CD40 agonist for the treatment or prevention of conditions wherein the enhancement of humoral immunity is therapeutically beneficial. Also, the invention relates to the use of VISTA antagonists alone or in association with another immune agonist, e.g., an iNOS/NO inhibitor or a CD40 agonist to promote the efficacy of therapeutic and prophylactic vaccines, e.g., antitumor, and antiviral vaccines.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式